2070015-00-6
物理化學(xué)性質(zhì)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-18163A | GNE-7915 tosylate | 2070015-00-6 | 5 mg | 500元 |
2024/11/08 | HY-18163A | GNE-7915 tosylate | 2070015-00-6 | 10mM * 1mLin DMSO | 677元 |
2024/11/08 | HY-18163A | GNE-7915 tosylate | 2070015-00-6 | 10mg | 895元 |
常見問題列表
IC50: 9 nM (LRRK2)
Maintaining the methoxy/fluoro arrangement at C-2′/C-5′ and varying aminoalkyl R1 substitution resultes in single-digit nanomolar LRRK2 cellular activities for GNE-7915 and compound 19. Expanded Invitrogen kinase profiling (187 kinases) at 0.1 μM for both GNE-7915 (100-fold over LRRK2 Ki) and 19 (250-fold over LRRK2 Ki) resultes in only TTK showing greater than 50% inhibition. Selectivity profiling using the DiscoverX KinomeScan55 competitive binding assay panel, which includes 392 unique kinases, is also performed for GNE-7915 at 0.1 μM. Binding of >50% probe displacement is detected for 10 kinases and of >65% for only LRRK2, TTK, and ALK, further supporting the excellent LRRK2 selectivity for GNE-7915. Cerep receptor profiling, including expanded brain panels, suggestes that GNE-7915 and 19 only inhibite 5-HT 2B with >70% inhibition at 10 μM. GNE-7915 and 19 are confirmed to be moderately potent 5-HT 2B antagonists in vitro functional assays.